BPS Bioscience, Inc. Announces New PARP Screening and Profiling Services

PRLog (Press Release) - Feb. 19, 2013 - SAN DIEGO, CA (February 19, 2013) – BPS Bioscience, Inc. (“BPS”) announced the expansion of its panel of PARP enzymes for screening and profiling of potential inhibitors.   BPS Bioscience’s unique panel now includes 12 different PARP isozymes, including PARPs 8, 11, 12 and 15.  

PARP (Poly (ADP-ribose) polymerase) is a family of enzymes that play important roles in chromatin structure, DNA repair, and apoptosis.  PARP is overexpressed in a number of human cancers, and its expression correlates with an aggressive phenotype and resistance to DNA damage-inducing therapeutic agents.  PARP inhibitors are an exciting new class of anti-cancer drugs that can act as both chemo- and radio-sensitizers as well as prevent repair to DNA damage.  Early clinical studies suggest PARP inhibitors show particular promise for breast and ovarian cancers with mutations in the PTEN, BRCA1 or BRCA2 genes.  

Researchers have identified at least 16 different members of the PARP family, which vary widely in their functions, tissue distribution, and subcellular localization.  Determining the isozyme-specific effects of small molecule PARP inhibitors is a critical step in the development of these compounds as diagnostic or therapeutic tools.

“BPS has been providing first class screening and profiling services to pharmaceutical and academic research  communities since 2007.  These novel PARP assays will enable our customers to assay an even wider range of PARP isoforms,” said Henry Zhu, President and CEO, BPS Biosciences, Inc.  "BPS continues to develop new assays and other specialized solutions to help researchers drive lead compounds through their development pipelines.”

In addition to expanding the service portfolio, BPS provides the largest commercially available selection of PARP isozymes, assay kits, substrates, inhibitors, and other tools for PARP research.  These newest PARP assays complement the broad array of drug discovery tools and world class custom biochemical services already offered by BPS.

To learn more about BPS Bioscience’s PARP services please visit http://bpsbioscience.com/images/pdf/PARP_profiling.pdf, and to learn more about all of the PARP products BPS offers please visit http://bpsbioscience.com/poly-adp-ribose-polymerase.  

About BPS Bioscience, Inc.

Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Methyltransferases, Kinases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases (PARPs), Proteases, Ubiquitin Enzymes, Methyl-lysine Readers and other Metabolic Enzymes.  BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products.  BPS also provides custom protein expression, biochemical and cell based assays, and compound screening and profiling services.  BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide.  By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases.  Visit BPS’s website for more information: http://www.bpsbioscience.com.